References of "Beckers, Albert"
     in
Bookmark and Share    
See detailCharacterization of prolatinomas resistant to dopaminergic agonists
Vroonen, Laurent ULg; Daly, Adrian ULg; Beckers, Albert ULg

in ENDO 2010 : The 92nd Annual Meeting (2010, June)

Detailed reference viewed: 12 (3 ULg)
See detailFamilial Isolated Pituitary Adenomas
Beckers, Albert ULg

Scientific conference (2010, June)

Detailed reference viewed: 10 (2 ULg)
See detailAdénomes hypophysaires familiaux
Beckers, Albert ULg

Scientific conference (2010, May 28)

Detailed reference viewed: 11 (2 ULg)
Full Text
See detailLa pathologie hypothalamo-hypophysaire post-traumatique
VALDES SOCIN, Hernan Gonzalo ULg; Beckers, Albert ULg

Conference (2010, April 24)

Detailed reference viewed: 12 (3 ULg)
See detailProblèmes hypophysaires suite à une lésion cérébrale aigüe
Beckers, Albert ULg

Scientific conference (2010, April 23)

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailThe R304X mutation of the Aryl hydrocarbon receptor Interacting Protein gene in familial isolated pituitary adenomas: mutational Hot-Spot or founder effect?
Occhi, G.; Jaffrain-Rea, M. L.; Trivellin, G. et al

in Journal of Endocrinological Investigation (2010), 33

Background: Mutations in the Aryl hydrocarbon receptor Interacting Protein (AIP) gene have been described in about 15% of kindreds with Familial Isolated Pituitary Adenomas (FIPA) and in a minority of ... [more ▼]

Background: Mutations in the Aryl hydrocarbon receptor Interacting Protein (AIP) gene have been described in about 15% of kindreds with Familial Isolated Pituitary Adenomas (FIPA) and in a minority of early onset sporadic pituitary adenomas (PA). Among the AIP mutations reported so far, the R304X (AIPR304X) represents, together with the "Finnish mutation" Q14X, the most common one. Methods: Three AIPR304X Italian families, including a newly reported kindred, have been genotyped for 12 genetic markers surrounding the AIP gene in order to look for a potential founder effect in Italy. Disease penetrance and genotype-phenotype correlations were also addressed. Results: Analysis of chromosome 11' genetic markers revealed a common haplotype in two AIPR304X kindreds originating from central Italy. Overall, seventeen mutations carriers were identified, including 7 patients and 10 unaffected subjects, respectively, arguing in this case for a disease penetrance of 41%. Mean age at diagnosis was 19.1+/-6.7 years-old, with females tending to be older than males. Though most PA were somatotropinomas (6/7), a great variability in disease severity was observed, even between subjects sharing the same at-risk haplotype. Conclusion: These data provide strong evidence for a new founder effect of the AIPR304X mutation in central Italy and the observed variations in disease severity point out the role of additional genetic or environmental factors in such kindreds. [less ▲]

Detailed reference viewed: 48 (4 ULg)
See detailRecent Management of acromegaly
Beckers, Albert ULg

Scientific conference (2010, March)

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailHigher prevalence of clinically relevant pituitary adenomas confirmed.
Beckers, Albert ULg

in Clinical Endocrinology (2010), 72(3), 290-291

Detailed reference viewed: 13 (7 ULg)
See detailAdénomes hypophysaires familiaux
Beckers, Albert ULg

Scientific conference (2010, February 27)

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailRisk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients.
Goudet, P.; Murat, A.; Binquet, C. et al

in World Journal of Surgery (2010), 34(2), 249-255

Background - The natural history of multiple endocrine neoplasia type 1 (MEN1) is known through single-institution or single-family studies. We aimed to analyze the risk factors and causes of death in a ... [more ▼]

Background - The natural history of multiple endocrine neoplasia type 1 (MEN1) is known through single-institution or single-family studies. We aimed to analyze the risk factors and causes of death in a large cohort of MEN1 patients. Methods - Overall, 758 symptomatic MEN1 patients were identified through the GTE network (Groupe d’étude des Tumeurs Endocrines), which involves French and Belgian genetics laboratories responsible for MEN1 diagnosis and 80 clinical reference centers. The causes of death were analyzed. A frailty model, including time-dependent variables, was used to assess the impact of each clinical lesion, except for hyperparathyroidism, on survival. Results - The median follow-up was 6.3 years. Female gender, family history of MEN1, and recent diagnosis were associated with a lower risk of death. Compared with nonaffected patients, those with thymic tumors (hazard ratio [HR] = 4.64, 95% CI = 1.73-12.41), glucagonomas–vipomas–somatostatinomas (HR = 4.29, 95% CI = 1.54-11.93), nonfunctioning pancreatic tumors (HR = 3.43, 95% CI = 1.71-6.88), and gastrinoma (HR = 1.89, 95% CI = 1.09-3.25) had a higher risk of death after adjustment for age, gender, and diagnosis period. The increased risk of death among patients with adrenal tumors was not significant, but three patients died from aggressive adrenal tumors. Pituitary tumors, insulinomas, and bronchial tumors did not increase the risk of death. The proportion of MEN1-related deaths decreased from 76.8 to 71.4% after 1990. Conclusions - The prognosis of MEN1 disease has improved since 1980. Thymic tumors and duodenopancreatic tumors, including nonsecreting pancreatic tumors, increased the risk of death. Rare but aggressive adrenal tumors may also cause death. Most deaths were related to MEN1. New recommendations on abdominal and thoracic imaging are required. [less ▲]

Detailed reference viewed: 29 (2 ULg)
Full Text
Peer Reviewed
See detailThe role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes.
Stratakis, C. A.; Tichomirowa, M. A.; Boikos, S. et al

in Clinical Genetics (2010)

The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. The prevalence of ... [more ▼]

The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. The prevalence of germline mutations in MEN1, AIP, PRKAR1A, CDKN1B and CDKN2CI is unknown among pediatric patients with pituitary adenomas (PA). In this study, we screened children with PA for mutations in these genes; somatic GNAS mutations were also studied in a limited number of growth hormone (GH) or prolactin (PRL)-secreting PA. We studied 74 and 6 patients with either isolated Cushing disease (CD) or GH- or PRL-secreting PA, respectively. We also screened four pediatric patients with CD, and four with GH/PRL-secreting tumors who had some syndromic features. There was one AIP mutation (p.Lys103Arg) among 74 CD patients. Two MEN1 mutations that occurred in patients with recurrent or difficult-to-treat disease were found among patients with CD. There was one MEN1 and three AIP mutations (p.Gln307ProfsX104, p.Pro114fsX, p.Lys241X) among pediatric patients with isolated GH- or PRL-secreting PA and one additional MEN1 mutation in a patient with positive family history. There were no mutations in the PRKAR1A, CDKN1B, CDKN2C or GNAS genes. Thus, germline AIP or MEN1 gene mutations are frequent among pediatric patients with GH- or PRL-secreting PA but are significantly rarer in pediatric CD; PRKAR1A mutations are not present in PA outside of Carney complex. [less ▲]

Detailed reference viewed: 40 (15 ULg)
See detailScreening for AIP mutations in young patients with pituitary macroadenomas
Jaffrain-Réa, M. L.; Tichomirova, M.; Angelini, M. et al

in 5° Incontro Italiano Malattie Ipotalamo Ipofisarie (2010, January)

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailFamilial pituitary adenomas
vandeva, s; Vasilev, V.; Vroonen, Laurent ULg et al

in Annales d'Endocrinologie (2010), 71

Detailed reference viewed: 29 (21 ULg)
Full Text
Peer Reviewed
See detailClinical characteristics and therapeutic responses in patients with Germ-line AIP mutations and pituitary adenomas : An international collaborative study
Daly, Adrian ULg; Tichomirowa, Maria A.; Petrossians, Patrick ULg et al

in Journal of Clinical Endocrinology and Metabolism (2010), 95(11),

Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features ... [more ▼]

Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features of AIPmut-associated pituitary adenomas have not been studied comprehensively. <br />Objective: The objective of the study was to assess clinical/therapeutic characteristics of AIPmut pituitary adenomas. <br />Design: This study was an international, multicenter, retrospective case collection/database analysis. <br />Setting: The study was conducted at 36 tertiary referral endocrine and clinical genetics departments. <br />Patients: Patients included 96 patients with germline AIPmut and pituitary adenomas and 232 matched AIPmut-negative acromegaly controls. <br />Results: The AIPmut population was predominantly young and male (63.5%); first symptoms occurred as children/adolescents in 50%. At diagnosis, most tumors were macroadenomas (93.3%); extension and invasion was common. Somatotropinomas comprised 78.1% of the cohort; there were also prolactinomas (n = 13), nonsecreting adenomas (n = 7), and a TSH-secreting adenoma. AIPmut somatotropinomas were larger (P = 0.00026), with higher GH levels (P = 0.00068), more frequent extension (P = 0.018) and prolactin cosecretion (P = 0.00023), and occurred 2 decades before controls (P < 0.000001). Gigantism was more common in the AIPmut group (P < 0.000001). AIPmut somatotropinoma patients underwent more surgical interventions (P = 0.00069) and had lower decreases in GH (P = 0.00037) and IGF-I (P = 0.028) and less tumor shrinkage with somatostatin analogs (P < 0.00001) vs. controls. AIPmut prolactinomas occurred generally in young males and frequently required surgery or radiotherapy. <br />Conclusions: AIPmut pituitary adenomas have clinical features that may negatively impact treatment efficacy. Predisposition for aggressive disease in young patients, often in a familial setting, suggests that earlier diagnosis of AIPmut pituitary adenomas may have clinical utility. [less ▲]

Detailed reference viewed: 110 (48 ULg)
Full Text
Peer Reviewed
See detailLe tabac et ses effets sur le système endocrinien
VALDES SOCIN, Hernan Gonzalo ULg; VROONEN, Laurent ULg; Latta, A. et al

in Revue Médicale de Liège (2010), 65(9), 498-501

Detailed reference viewed: 16 (2 ULg)
See detailYoung patients with sporadic pituitary macroadenomas as target population of AIP mutation screening
Tichomirova, M.; Daly, Adrian ULg; Beckers, Albert ULg

in 12th European Congress of Endocrinology - ICE 2010 (2010)

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailConcepts actuels de l'hyperaldostéronisme primaire
Vroonen, Laurent ULg; Krzesinski, Jean-Marie ULg; Hamoir, Etienne ULg et al

in Revue Médicale de Liège (2010), 65(10), 583-587

Detailed reference viewed: 37 (14 ULg)